Library›Substances and pharmacology›Psychotomimetics Sedation and the Evolution of Psychiatry

Psychotomimetics Sedation and the Evolution of Psychiatry

Psychotomimetics, Sedation, and the Evolution of Psychiatry traces the historical paradigms of psychiatric medicine—from early "model psychosis" hypotheses and involuntary institutional experiments to surgical and chemical sedation (ether, chlorpromazine, barbiturates), the evolution of hypnotic sleeping aids, the cathinone pharmacology of Wellbutrin, and the contrasting neurocircuitry of generalized anxiety, paranoid anxiety, and Post-Traumatic Stress Disorder (PTSD).

The "Psychotomimetic" Hypothesis and Early Schizophrenia Research

In the 1950s, modern psychopharmacology was born out of an attempt to discover the biological etiology of schizophrenia. Early psychiatrists and chemists—including Humphry Osmond, Abram Hoffer, John Smythies, and Ralph Gerard—observed that mescaline and the newly discovered lysergic acid diethylamide (LSD) produced profound perceptual distortions, synesthesia, and cognitive alterations in healthy subjects:

<code>

[ THE EARLY PSYCHOTOMIMETIC HYPOTHESIS (1950s) ]

│

┌───────────────────────────┴───────────────────────────┐

▼ ▼

[ Exogenous Hallucinogen ] [ Endogenous Schizophrenia ]

• Mescaline / LSD / Psilocin • Aberrant metabolic toxin ("M-Substance")

• Believed to chemically "mimic" • Adrenochrome hypothesis (oxidized adrenaline)

true schizophrenia • Goal: Isolate the "toxin" to find the "cure"

</code>

The "Model Psychosis": Because these compounds produced visions and unusual ideation, they were initially classified as "psychotomimetics" (literally, *psychosis-mimicking* agents) or "hallucinogens".
The Endogenous Toxin Search: Researchers hypothesized that schizophrenia was caused by an inborn error of metabolism producing an endogenous psychotomimetic toxin—such as adrenochrome (an oxidation product of epinephrine) or abnormal methylated phenethylamines (the "M-substance").
Shulgin's Early Engagement: Alexander "Sasha" Shulgin began his chemical career within this exact intellectual climate. His early work synthesizing mescaline analogues and the trimethoxyamphetamine (TMA) series was originally framed as an effort to map structure-activity relationships that might uncover the biochemical trigger of clinical schizophrenia.

1. The Coining of "Psychedelic"

By 1956, Humphry Osmond recognized that the term "psychotomimetic" was fundamentally flawed: it focused entirely on fear, confusion, and pathology while ignoring the profound aesthetic beauty, emotional catharsis, mystical unity, and cognitive expansion reported by healthy subjects. In a famous rhyming correspondence with Aldous Huxley, Osmond coined the term "psychedelic" (from the Greek *psyche*, "mind/soul", and *deloun*, "to manifest or reveal"):

: "To fathom Hell or soar angelic, just take a pinch of psychedelic."

2. Shulgin's Critique of Institutional and Prison Studies

In his later writings, particularly in PIHKAL and TIHKAL, Shulgin delivered scathing critiques of the early government and university experiments conducted at facilities such as the Lexington Addiction Research Center in Kentucky and Holmesburg Prison in Pennsylvania (often funded under the CIA's MKUltra program):

The Neglect of Set and Setting: Institutional researchers administered massive doses of LSD, mescaline, or synthetic analogues (such as Ditran or BZ) to incarcerated inmates, institutionalized psychiatric patients, or unconsenting subjects who were physically strapped to hospital gurneys in sterile, hostile basement laboratories, surrounded by white-coated doctors taking cold clinical notes.
Manufactured Terror: Under these terrifying conditions, subjects naturally experienced profound panic, paranoia, sensory overload, and terror.
The Epistemological Blunder: Researchers recorded these terrified reactions as empirical "proof" that the drugs induced clinical psychosis. Shulgin argued that the researchers had not measured the pharmacology of the molecules; they had measured the psychological trauma of terrorizing a human being whose cognitive filters had been chemically dismantled. When taken in supportive, comfortable, aesthetic environments ("Set and Setting"), the exact same molecules produced peaceful, transcendent, and therapeutic states.

The Sedation Paradigm: From Ether to "Chemical Lobotomies"

For over a century, institutional psychiatry operated on a single core therapeutic strategy: emotional and behavioral blunting. If a patient was agitated, manic, psychotic, or severely distressed, the intervention was to depress the central nervous system until the behavioral symptom was silenced:

<code>

[ THE PARADIGM OF SUPPRESSION ]

│

┌──────────────────────────────┼──────────────────────────────┐

▼ ▼ ▼

[ Volatile Anesthetics ] [ Barbiturate Era ] [ Typical Antipsychotics ]

• Ether & Chloroform • Phenobarbital, Secobarbital • Chlorpromazine (Thorazine)

• Global neuronal shutdown • Direct GABAA pore openers • Pure D2 dopamine blockade

• Surgical suppression • Extreme fatal overdose risk • "Chemical Lobotomy" / Apathy

</code>

1. Volatile Depressants and Dental Analgesia

In the 19th and early 20th centuries, volatile hydrocarbon solvents—diethyl ether, chloroform, and high-dose ethyl alcohol—were the primary agents used to extinguish conscious agitation, both for surgical procedures and in asylum management.
These agents cause non-specific membrane disruption and diffuse potentiation of inhibitory receptors, inducing global central nervous system depression.

2. The Barbiturate Era and Its Fatal Flaw

In the early 20th century, barbiturates (synthesized from barbituric acid: phenobarbital, pentobarbital, secobarbital / "reds", amobarbital) became the standard treatment for anxiety, mania, and insomnia.
Mechanism of Action: Barbiturates bind allosterically to the $\text{GABA}_A$ receptor. Crucially, at therapeutic doses they prolong the duration of channel opening in the presence of GABA; at higher doses, they act as direct $\text{GABA}_A$ receptor agonists, forcing the chloride channel open *even in the complete absence of endogenous GABA*.
The Overdose Hazard: This direct gating activity produces an absence of a pharmacological "ceiling effect." By flooding neurons with hyperpolarizing chloride ions, barbiturates shut down respiratory pacemaker neurons in the pre-Bötzinger complex of the brainstem, leading to fatal respiratory arrest. Barbiturates possessed a razor-thin therapeutic index, making accidental death and suicide routine occurrences.

3. The First-Generation Antipsychotics: Thorazine as a "Chemical Lobotomy"

In 1952, French surgeons and psychiatrists discovered that chlorpromazine (Thorazine)—originally synthesized as an antihistamine—calmed agitated surgical and psychiatric patients without inducing general anesthesia.
The Dopamine $D_2$ Blockade: Chlorpromazine and its successor haloperidol (Haldol) act as high-affinity antagonists at the dopamine $D_2$ receptor in the mesolimbic, mesocortical, and nigrostriatal pathways.
Neuroleptic Malignant Blunting: While chlorpromazine suppressed acute positive psychotic symptoms (delusions, auditory hallucinations) by blocking mesolimbic dopamine transmission, it simultaneously blocked nigrostriatal and mesocortical dopamine, inducing profound side effects:

** Extrapyramidal Symptoms (EPS): Parkinsonian tremors, muscle rigidity, and acute dystonia.

** Tardive Dyskinesia: Permanent, irreversible involuntary facial and tongue tics caused by dopamine receptor hypersensitivity.

** Neuroleptic Induced Dysphoria / Affective Blunting: Patients described Thorazine as a "chemical lobotomy." It did not resolve underlying psychological distress; rather, it rendered the patient emotionally indifferent, cognitively sluggish, and incapable of feeling pleasure or initiating spontaneous thought.

Second-Generation Atypicals: Later atypical antipsychotics (olanzapine, quetiapine, risperidone) introduced concurrent $5\text{-HT}_{2A}$ receptor antagonism, which stimulates downstream dopamine release specifically in the nigrostriatal pathway to mitigate extrapyramidal motor tremors, yet the core mechanism remains dopaminergic suppression.

The Evolution of Sleeping Pill Technology

The quest to induce restorative sleep without the lethal respiratory depression of barbiturates drove a multi-generational evolution in sedative-hypnotic pharmacology:

{| class="wikitable"

! Generation !! Class / Representative Drug !! Primary Molecular Target !! Pharmacological Profile !! Clinical Drawbacks

| 1st Gen: Antihistamines || Doxylamine Succinate (The NyQuil Molecule), Diphenhydramine || Histamine $H_1$ receptor inverse agonist; Muscarinic $M_1$ antagonist || Sedation via central histaminergic blockade; over-the-counter availability. || Heavy morning cognitive "hangover"; next-day brain fog; rapid tolerance; strong anticholinergic load (dry mouth, urinary retention).

| 2nd Gen: Barbiturates || Secobarbital, Pentobarbital || $\text{GABA}_A$ receptor (Direct pore opening at high doses) || Profound, deep central sedation; suppression of REM sleep. || Extreme fatal overdose risk; severe physiological dependence; lethal withdrawal seizures; narrow therapeutic window.

| 3rd Gen: Benzodiazepines || Temazepam (Restoril), Flurazepam, Triazolam || $\text{GABA}_A$ receptor Positive Allosteric Modulator (PAM) || Binds $\alpha/\gamma$ interface; increases channel opening *frequency*; ceiling effect prevents isolated fatal arrest. || Tolerance within 2–4 weeks; disruption of deep slow-wave and REM sleep architecture; severe physical dependence and protracted withdrawal.

| 4th Gen: "Z-Drugs" || Zolpidem (Ambien), Zaleplon (Sonata), Eszopiclone (Lunesta) || Selective $\text{GABA}_A$ $\alpha_1$ subunit Positive Allosteric Modulator || Preferentially targets the sedative/hypnotic $\alpha_1$ subunit over $\alpha_2/\alpha_3$ (anxiolytic) or $\alpha_5$ (cognitive). || Rapid onset; less muscle relaxation; prone to complex amnesic sleep behaviors (sleep-eating, sleep-driving, parasomnias).

| 5th Gen: Orexin Antagonists (DORAs) || Suvorexant (Belsomra), Lemborexant (Dayvigo) || Dual Orexin Receptor Antagonists ($\text{OX}_1\text{R}$ and $\text{OX}_2\text{R}$) || Blocks wake-promoting neuropeptides (orexin A & B) rather than forcing global GABAergic inhibition. || Preserves natural REM and NREM sleep stages; non-habit forming; high financial cost.

The "NyQuil Molecule": Doxylamine Succinate

Doxylamine succinate is one of the most potent sedative antihistamines known—materially more sedating than diphenhydramine (Benadryl).
It produces drowsiness by crossing the blood-brain barrier and blocking wake-promoting histamine neurons in the tuberomammillary nucleus (TMN) of the posterior hypothalamus.
However, because it is also a potent antagonist at muscarinic acetylcholine receptors, it impairs acetylcholine signaling in the hippocampus, producing the classic "NyQuil hangover"—prolonged cognitive sluggishness and impaired memory retention the following morning.

The Z-Drug Revolution: Zolpidem (Ambien)

Traditional benzodiazepines bind indiscriminately to $\text{GABA}_A$ receptors containing $\alpha_1$, $\alpha_2$, $\alpha_3$, and $\alpha_5$ subunits, producing broad sedation, muscle relaxation, anxiolysis, and cognitive impairment.
Zolpidem (Ambien) was engineered as an imidazopyridine that selectively binds the $\alpha_1$ subunit, which is concentrated in the cortex and thalamus and mediates sedation specifically.
While Ambien spared muscle tone and anxiolytic circuits, its high-affinity $\alpha_1$ activation can uncouple conscious awareness from motor execution: if a user resists immediate sleep, the cortex enters a waking hypnotic state characterized by profound retrograde amnesia and complex automatisms (sleep-walking, preparing meals, or driving while entirely asleep).

Antidepressants: SSRI Emotional Blunting vs. The Wellbutrin (Cathinone) Engine

Modern antidepressant therapy exhibits a fundamental chemical divide between serotonergic stabilizers and substituted cathinones:

<code>

[ SSRI PARADIGM (Fluoxetine, Sertraline) ] [ WELLBUTRIN PARADIGM (Bupropion) ]

│ │

▼ ▼

[ Pure SERT Blockade ] [ Substituted Cathinone ]

• Elevates synaptic serotonin • 3-Chloro-N-tert-butylcathinone

• Suppresses limbic reactivity • Dual NET + DAT inhibitor (NDRI)

• Emotional blunting / "apathy syndrome" • Non-competitive nAChR antagonist

• High rate of sexual dysfunction • Zero serotonergic action / Anti-fatigue

• Weight gain & emotional flattening • Preserves sexual function & drive

</code>

1. SSRI Emotional Blunting ("The SSRI Smile")

Selective Serotonin Reuptake Inhibitors (SSRIs) successfully prevent depressive despair by elevating synaptic serotonin and downregulating hyperactive amygdala circuits.
However, in up to 50% of chronic patients, high serotonergic tone exerts an inhibitory break on ventral tegmental area (VTA) dopamine firing via $5\text{-HT}_{2C}$ receptors.
This results in SSRI-induced apathy syndrome: patients no longer feel bottomless sorrow, but they simultaneously lose the capacity to feel intense joy, romantic passion, artistic inspiration, or sexual libido. The emotional peaks and valleys are compressed into a flat, gray plateau.

2. Wellbutrin (Bupropion) Is a Substituted Cathinone

Few patients or clinicians realize that Wellbutrin (bupropion) is chemically a substituted cathinone—a direct structural derivative of the natural alkaloid cathinone found in the East African shrub Khat (Catha edulis).
Chemically, bupropion is 3-chloro-$N$-tert-butyl-$\beta$-ketoamphetamine:

: <code>Cathinone: C6H5─CO─CH(CH3)─NH2  ──►  Bupropion: 3-Cl─C6H4─CO─CH(CH3)─NH(C(CH3)3)</code>

The Bulky $N$-tert-Butyl Shield:

** By placing a chlorine atom at the 3-position and attaching a bulky, branched tert-butyl group to the amine, medicinal chemists created a molecule that completely avoids the neurotoxic serotonin-releasing profile of recreationally abused cathinones.

** Bupropion acts as a selective Norepinephrine-Dopamine Reuptake Inhibitor (NDRI).

** Furthermore, bupropion acts as a potent non-competitive antagonist at nicotinic acetylcholine receptors (nAChR) (specifically $\alpha_3\beta_4$ and $\alpha_4\beta_2$ subtypes), which explains why it is independently marketed as Zyban for smoking cessation: it physically blocks nicotine from triggering dopamine reward spikes in the ventral striatum.

Because bupropion does not elevate serotonin, it is completely free of SSRI emotional blunting, lethargy, weight gain, and sexual dysfunction. Instead, it provides clean executive focus, motivation, and physical energy.

The Neurocircuitry of Fear: Anxiety vs. Paranoid Anxiety vs. PTSD

To develop effective therapies—especially for military combat veterans—psychiatry must delineate the distinct neurocircuits that drive distress:

<code>

[ GENERALIZED ANXIETY ] [ PARANOID ANXIETY ] [ POST-TRAUMATIC STRESS (PTSD) ]

│ │ │

▼ ▼ ▼

[ Sympathetic Hyper-Arousal ] [ Aberrant Salience ] [ Trauma Reconsolidation Lock ]

• Hyperactive Locus Coeruleus • Striatal Dopamine runaway • Amygdala fear memory frozen

• Excess Norepinephrine / Epinephrine • Neutral events tagged as threats • Medial PFC fails to gate amygdala

• Tachycardia, tremors, tension • Delusional intent & persecution • Flashbulb flashbacks & dissociation

• "The body cannot calm down" • "They are watching / coordinating" • "The war is happening right now"

</code>

1. Generalized Anxiety: Sympathetic Overdrive

Driven primarily by an hyper-excitable noradrenergic axis originating in the brainstem locus coeruleus.
Characterized by excessive peripheral autonomic signaling: muscle tension, shallow breathing, racing heart, and generalized somatic worry. The threat is diffuse and unfocused; the biological alarm system is simply set to an excessively sensitive threshold.

2. Paranoid Anxiety: The Dopaminergic Attribution of Hostile Intent

Represents an intersection between anxiety and psychosis driven by dopaminergic aberrant salience.
When dopamine surges inappropriately in the dorsal and ventral striatum, the brain assigns urgent personal significance to random sensory stimuli.
The anxious cognitive cortex attempts to explain this heightened salience by concluding that neutral external agents (neighbors, passing cars, coworkers, government entities) are acting with deliberate, coordinated hostile intent. The individual feels under active surveillance or persecution.

3. Post-Traumatic Stress Disorder (PTSD): The Frozen Synaptic Circuit

PTSD is not simply "severe anxiety"; it is a specific structural failure of memory reconsolidation and prefrontal inhibitory gating:

Hyperactive Basolateral Amygdala: During severe life-threatening trauma (combat, catastrophic assault), massive surges of norepinephrine and cortisol burn an indelible, hyper-consolidated fear trace into the synapses of the basolateral amygdala (BLA).
Prefrontal Cortex (mPFC) Hypo-Activity: Under normal conditions, the medial prefrontal cortex evaluates safe environments and sends inhibitory GABAergic signals down to the amygdala to extinguish fear responses. In PTSD patients, neuroimaging demonstrates that the mPFC is physically hypo-active and structurally atrophied: it cannot exert top-down inhibition over the amygdala.
Hippocampal Dysregulation: The hippocampus fails to contextualize the memory in time and space. Consequently, an environmental trigger (a car backfire, a loud shout, a specific smell) does not produce a conscious memory of the past; it triggers an instantaneous, full-body flashbulb re-experiencing: to the veteran's nervous system, the mortal threat is happening right now in the room.

Why Traditional Suppression Fails Veterans with PTSD

The historic institutional response to veteran trauma was to administer high doses of first-generation antipsychotics (Thorazine), second-generation neuroleptics (Seroquel), and heavy benzodiazepines (Xanax, Klonopin).
The Failure of Blunting: While benzodiazepines temporarily silence acute somatic panic by forcing GABAergic inhibition, they actively block fear extinction learning.
To heal trauma, the amygdala must retrieve the fearful memory while the subject is in a safe neurochemical state, allowing the brain to update the memory with safe contextual data (memory reconsolidation).
Benzodiazepines cause retrograde amnesia and blunt synaptic plasticity, physically preventing the brain from rewiring the trauma circuit. The veteran remains biochemically dependent on the sedative, while the frozen amygdala trauma loop remains entirely intact beneath the chemical fog.

Filed under Substances and pharmacology Organic chemistry and synthesis